Fundraising Fox
Ancora Heart
Santa Clara, US · Delaware corporation · 79 employees on LinkedIn · 1 known investors
Find your way into Ancora Heart
224 people in our graph share verified history with the Ancora Heart team — schools, employers, funds. One of them is your warm intro.
Naveen Yalamanchiunlockedknows Mark Miles · together at Ancora Heart, Inc. (overlapped)
×3knows the team · via Invuity, Inc.
×8knows the team · via Pepperdine Graziadio Business School
Ancora Heart develops minimally invasive medical devices, including a class III implantable therapy for cardiovascular treatment. The company focuses on cardiac/heart failure therapy development, clinical research, and commercialization of its core technology.
Founders & leadership
JM
Jeffrey M. ClossPresident & CEO
RS
Russel SampsonChief Technical Officer
MM
Mark MilesChief Commercial OfficerMark Miles has 25 years of executive leadership in medical device, biotech, and pharmaceutical companies, with expertise spanning commercial strategy, operations, portfolio management, and product marketing. He has held roles leading commercial strategy for medical technology companies across cardiovascular, surgical, and pharmaceutical sectors, including experience with catheter-based devices, stent grafts, and surgical visualization technologies.
DC
David C. AuthNamed on SEC filing
RW
Robert W. CroceNamed on SEC filing
LC
Lewis C. PellNamed on SEC filing
AM
Andrew MidlerNamed on SEC filing
Investors · 1
Sands Capital VenturesreportedArlington · $10M – $30M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$121.3M disclosed across 3 rounds · 2018–2021
▶$80MraisedJul 2021 · 47 investors · Other Health CareRule 506(b)
▶$80MraisedJul 2021 · 47 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lewis C. PellDirector
- Jeffrey ClossExecutive Officer, Director
- Robert W. CroceDirector
- Andrew MidlerDirector
- Beverly A. HussDirector
- David C. AuthDirector
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.5MraisedDec 2018 · 5 investors · Other Health CareRule 506(b)
▶$23.5MraisedDec 2018 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert W. CroceDirector
- Andrew MidlerDirector
- David C. AuthDirector
- Jeffrey ClossExecutive Officer, Director
- Lewis C. PellDirector
- Offering amount
- $35M
- Amount sold
- $23.5M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.8MraisedMay 2018 · 32 investors · Other Health CareRule 506(b)
▶$17.8MraisedMay 2018 · 32 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David C. AuthDirector
- Robert W. CroceDirector
- Jeffrey ClossExecutive Officer, Director
- Lewis C. PellDirector
- Andrew MidlerDirector
- Offering amount
- $30M
- Amount sold
- $17.8M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Ancora Heart.
In the news
Frequently asked questions
- What does Ancora Heart do?
- Ancora Heart develops minimally invasive medical devices, including a class III implantable therapy for cardiovascular treatment. The company focuses on cardiac/heart failure therapy development, clinical research, and commercialization of its core technology.
- Who are Ancora Heart's investors?
- Ancora Heart's investors include Sands Capital Ventures.
- How much funding has Ancora Heart raised?
- Ancora Heart has disclosed $121.3M raised across 3 rounds.
- Where is Ancora Heart headquartered?
- Ancora Heart is headquartered in Santa Clara, US.